Articles by Daniel Marsh
Nasdaq Hits Record as Intel AI Outlook Fuels Chip Rally, Dow Dips
The Nasdaq hit a new intraday high Friday as Intel's strong Q2 outlook sparked a broad chip rally, while the Dow slipped. Consumer sentiment hit a record low, keeping inflation worries front and center.
Lilly's Oral Obesity Drug Foundayo Trails Novo Nordisk's Wegovy in Early Prescription Data
Eli Lilly's Foundayo prescriptions hit 3,707 in week two, well behind Novo Nordisk's Wegovy. Lilly shares dropped 4%, while Novo gained 6%. Analysts advise caution on early figures.
Cheetah Net Soars on Acquisition Deal, Heavy Trading Volume
Cheetah Net shares jumped on heavy volume after agreeing to buy Super International Trading for $4.98M in cash, with a $10M annual revenue target.
FreeCast Soars on DIRECTV Multifamily Deal, Financing Risks Remain
FreeCast shares jumped 23.8% on a DIRECTV multifamily deal. Maxim Group initiated with Buy and $6 target. Dilution risks persist per SEC filings.
Novo Nordisk Wegovy Pill Prescriptions Surge Past Eli Lilly's Foundayo in Early Launch Race
Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly's Foundayo at 3,707, according to IQVIA data. Novo shares rose, Lilly fell.
Elong Power Stock Surges 26% on Heavy Volume Amid Turnaround Efforts
Elong Power shares surged 26% on heavy trading volume, as the company released its annual report showing narrowed losses and a strategic pivot to an asset-light battery storage model.
Scinai Immunotherapeutics Soars 82% on $2.61M Private Placement for CDMO Expansion
Scinai Immunotherapeutics shares surged 82% after announcing a $2.61M private placement to support its CDMO expansion and immunotherapy programs.
Organon Surges on Report of $13B Sun Pharma Bid
Organon shares jumped 25% Friday after a report that Sun Pharma made a $13 billion all-cash takeover offer, backed by $12 billion in bank financing.
Regeneron Stock Rises on Drug Pricing Deal, Free Gene Therapy Offer
Regeneron shares gained 2.6% Thursday following a drug-pricing pact with the U.S. and a plan to offer its new gene therapy Otarmeni at no cost. Analysts remain optimistic ahead of Q1 results.
Lucid Shares Hit Record Low Despite Uber-Backed $1.05B Funding
Lucid shares tumbled 9.26% to $6.27, a new low, as a $1.05B funding package from Uber and Saudi PIF failed to ease dilution concerns.
Wren Kitchens Shutters All US Operations, Layoffs in Pennsylvania
Wren US Holdings has closed all US showrooms and studios, leading to layoffs in northeastern Pennsylvania, reversing a 2020 expansion that promised 360 jobs.